[Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].
Identifieur interne : 001716 ( Main/Corpus ); précédent : 001715; suivant : 001717[Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].
Auteurs : Anne Troldborg ; Lars Erik Bartels ; Bent DeleuranSource :
- Ugeskrift for laeger [ 1603-6824 ] ; 2020.
English descriptors
- KwdEn :
- Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Humans (MeSH), Hydroxychloroquine (pharmacology), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
- MESH :
- chemical , pharmacology : Antiviral Agents, Hydroxychloroquine.
- chemical , therapeutic use : Antiviral Agents, Hydroxychloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
The severity of COVID-19 disease has led to an urgent need for the discovery of new treatments. Thus, global stocks of hydroxychloroquine (HCQ) have been put under pressure with a study of 26 patients treated with HCQ during their infection with SARS-CoV-2. Despite the study's lack of quality, several countries' medicines agencies subsequently issued guidelines for the use of HCQ for COVID-19. This review aims to elucidate potential mechanisms, which make HCQ treatment interesting in the fight against SARS-CoV-2 infection, as well as the current evidence for clinical use of HCQ to treat COVID-19.
PubMed: 32400380
Links to Exploration step
pubmed:32400380Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].</title>
<author><name sortKey="Troldborg, Anne" sort="Troldborg, Anne" uniqKey="Troldborg A" first="Anne" last="Troldborg">Anne Troldborg</name>
<affiliation><nlm:affiliation>annetrol@rm.dk.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bartels, Lars Erik" sort="Bartels, Lars Erik" uniqKey="Bartels L" first="Lars Erik" last="Bartels">Lars Erik Bartels</name>
</author>
<author><name sortKey="Deleuran, Bent" sort="Deleuran, Bent" uniqKey="Deleuran B" first="Bent" last="Deleuran">Bent Deleuran</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32400380</idno>
<idno type="pmid">32400380</idno>
<idno type="wicri:Area/Main/Corpus">001716</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001716</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].</title>
<author><name sortKey="Troldborg, Anne" sort="Troldborg, Anne" uniqKey="Troldborg A" first="Anne" last="Troldborg">Anne Troldborg</name>
<affiliation><nlm:affiliation>annetrol@rm.dk.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bartels, Lars Erik" sort="Bartels, Lars Erik" uniqKey="Bartels L" first="Lars Erik" last="Bartels">Lars Erik Bartels</name>
</author>
<author><name sortKey="Deleuran, Bent" sort="Deleuran, Bent" uniqKey="Deleuran B" first="Bent" last="Deleuran">Bent Deleuran</name>
</author>
</analytic>
<series><title level="j">Ugeskrift for laeger</title>
<idno type="eISSN">1603-6824</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (pharmacology)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The severity of COVID-19 disease has led to an urgent need for the discovery of new treatments. Thus, global stocks of hydroxychloroquine (HCQ) have been put under pressure with a study of 26 patients treated with HCQ during their infection with SARS-CoV-2. Despite the study's lack of quality, several countries' medicines agencies subsequently issued guidelines for the use of HCQ for COVID-19. This review aims to elucidate potential mechanisms, which make HCQ treatment interesting in the fight against SARS-CoV-2 infection, as well as the current evidence for clinical use of HCQ to treat COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32400380</PMID>
<DateCompleted><Year>2020</Year>
<Month>05</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1603-6824</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>182</Volume>
<Issue>20</Issue>
<PubDate><Year>2020</Year>
<Month>05</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Ugeskrift for laeger</Title>
<ISOAbbreviation>Ugeskr Laeger</ISOAbbreviation>
</Journal>
<ArticleTitle>[Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">V04200213</ELocationID>
<Abstract><AbstractText>The severity of COVID-19 disease has led to an urgent need for the discovery of new treatments. Thus, global stocks of hydroxychloroquine (HCQ) have been put under pressure with a study of 26 patients treated with HCQ during their infection with SARS-CoV-2. Despite the study's lack of quality, several countries' medicines agencies subsequently issued guidelines for the use of HCQ for COVID-19. This review aims to elucidate potential mechanisms, which make HCQ treatment interesting in the fight against SARS-CoV-2 infection, as well as the current evidence for clinical use of HCQ to treat COVID-19.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Troldborg</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>annetrol@rm.dk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bartels</LastName>
<ForeName>Lars Erik</ForeName>
<Initials>LE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Deleuran</LastName>
<ForeName>Bent</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>dan</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Denmark</Country>
<MedlineTA>Ugeskr Laeger</MedlineTA>
<NlmUniqueID>0141730</NlmUniqueID>
<ISSNLinking>0041-5782</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="Y">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>5</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32400380</ArticleId>
<ArticleId IdType="pii">V04200213</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001716 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001716 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32400380 |texte= [Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32400380" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |